$GOVX News

Update - GeoVax Enters Into $1 Million Revolving Loan Agreement

GeoVax Enters Into $1 Million Revolving Loan Agreement

GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026

GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States

GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models

GeoVax Confirms Bundibugyo Ebola Vaccine Construct

Noble Capital Markets Maintains Outperform on Geovax Labs, Maintains $10 Price Target

GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial

GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities

GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply

GeoVax Announces a Warrant Inducement Transaction

GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation

GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak

GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies

GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak

GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway

GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study

GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio

GeoVax Labs (GOVX): High Growth Stock Beats Earnings, Advances Mpox Vaccine and Cancer Therapy

GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update